Anteris Technologies Files S-1 for Securities Registration

TL;DR

Anteris Tech files S-1, prepping for public offering. Watch this space.

AI Summary

Anteris Technologies Global Corp. filed an S-1 registration statement on November 22, 2024, to register securities under the Securities Act of 1933. The company, incorporated in Delaware, is involved in the orthopedic, prosthetic, and surgical appliances and supplies industry. Its principal executive offices are located in Eagan, Minnesota, with a principal executive officer being CEO Wayne Paterson.

Why It Matters

This S-1 filing indicates Anteris Technologies Global Corp. is preparing to offer securities to the public, which could impact its capital structure and future growth prospects.

Risk Assessment

Risk Level: medium — As an S-1 filing, it signifies a company seeking public investment, which inherently carries market and execution risks.

Key Numbers

• 333-283414 — SEC File Number (Identifies this specific registration filing with the SEC.)
• 3842 — SIC Code (Indicates the company operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry.)

Key Players & Entities

• Anteris Technologies Global Corp. (company) — Registrant
• November 22, 2024 (date) — Filing Date
• Securities Act of 1933 (legal_document) — Governing Legislation
• Wayne Paterson (person) — Chief Executive Officer
• Eagan, Minnesota (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ng of shares of common stock, par value $0.0001 per share ("Common Stock"), of Anteris
• $1 — is prospectus were made at the rate of A$1 to $0.6828, the noon buying rate on Dec
• $0 — spectus were made at the rate of A$1 to $0.6828, the noon buying rate on December
• $1.00 — buying rate for Australian dollars was A$1.00 to $0.6461. v TABLE OF CONTENTS P
• $0.6461 — te for Australian dollars was A$1.00 to $0.6461. v TABLE OF CONTENTS PROSPECTUS S

Filing Documents

• tm245520-18_s1.htm (S-1) — 4700KB
• tm245520d17_ex1-1.htm (EX-1.1) — 293KB
• tm245520d17_ex2-1.htm (EX-2.1) — 858KB
• tm245520d17_ex3-1.htm (EX-3.1) — 14KB
• tm245520d17_ex3-2.htm (EX-3.2) — 48KB
• tm245520d17_ex3-3.htm (EX-3.3) — 92KB
• tm245520d17_ex3-4.htm (EX-3.4) — 155KB
• tm245520d17_ex4-2.htm (EX-4.2) — 599KB
• tm245520d17_ex10-1.htm (EX-10.1) — 133KB
• tm245520d17_ex10-2.htm (EX-10.2) — 83KB
• tm245520d17_ex10-3.htm (EX-10.3) — 198KB
• tm245520d17_ex10-4.htm (EX-10.4) — 144KB
• tm245520d17_ex10-5.htm (EX-10.5) — 104KB
• tm245520d17_ex10-6.htm (EX-10.6) — 42KB
• tm245520d17_ex10-7.htm (EX-10.7) — 25KB
• tm245520d17_ex10-8.htm (EX-10.8) — 29KB
• tm245520d17_ex10-9.htm (EX-10.9) — 164KB
• tm245520d17_ex10-10.htm (EX-10.10) — 294KB
• tm245520d17_ex10-11.htm (EX-10.11) — 18KB
• tm245520d17_ex10-12.htm (EX-10.12) — 169KB
• tm245520d17_ex10-13.htm (EX-10.13) — 72KB
• tm245520d17_ex10-14.htm (EX-10.14) — 70KB
• tm245520d17_ex10-15.htm (EX-10.15) — 14KB
• tm245520d17_ex10-16.htm (EX-10.16) — 175KB
• tm245520d17_ex10-17a.htm (EX-10.17(A)) — 65KB
• tm245520d17_ex10-17b.htm (EX-10.17(B)) — 25KB
• tm245520d17_ex10-17c.htm (EX-10.17(C)) — 25KB
• tm245520d17_ex10-17d.htm (EX-10.17(D)) — 28KB
• tm245520d17_ex10-18.htm (EX-10.18) — 136KB
• tm245520d17_ex10-19a.htm (EX-10.19(A)) — 596KB
• tm245520d17_ex10-19b.htm (EX-10.19(B)) — 110KB
• tm245520d17_ex10-19c.htm (EX-10.19(C)) — 66KB
• tm245520d17_ex10-19d.htm (EX-10.19(D)) — 61KB
• tm245520d17_ex10-19e.htm (EX-10.19(E)) — 60KB
• tm245520d17_ex10-19f.htm (EX-10.19(F)) — 55KB
• tm245520d17_ex10-20a.htm (EX-10.20(A)) — 77KB
• tm245520d17_ex10-20b.htm (EX-10.20(B)) — 36KB
• tm245520d17_ex10-21.htm (EX-10.21) — 125KB
• tm245520d17_ex10-22.htm (EX-10.22) — 217KB
• tm245520d17_ex10-23.htm (EX-10.23) — 151KB
• tm245520d17_ex10-24.htm (EX-10.24) — 92KB
• tm245520d17_ex10-25.htm (EX-10.25) — 181KB
• tm245520d17_ex10-26.htm (EX-10.26) — 98KB
• tm245520d17_ex10-27.htm (EX-10.27) — 25KB
• tm245520d17_ex21-1.htm (EX-21.1) — 5KB
• tm245520d17_ex23-1a.htm (EX-23.1(A)) — 2KB
• tm245520d17_ex23-1b.htm (EX-23.1(B)) — 2KB
• tm245520d17_ex23-3.htm (EX-23.3) — 5KB
• tm245520d17_ex-filingfees.htm (EX-FILING FEES) — 19KB
• lg_anteris-4clr.jpg (GRAPHIC) — 11KB
• ph_transcatheter-4c.jpg (GRAPHIC) — 85KB
• ph_ourproducts-4c.jpg (GRAPHIC) — 44KB
• ph_anticalcification-4clr.jpg (GRAPHIC) — 28KB
• ph_comasurdelivery-4clr.jpg (GRAPHIC) — 23KB
• ph_system-4clr.jpg (GRAPHIC) — 70KB
• ph_commissures-4clr.jpg (GRAPHIC) — 133KB
• ph_firstballoon-4clr.jpg (GRAPHIC) — 20KB
• ph_balloonexpanded-4clr.jpg (GRAPHIC) — 20KB
• ph_finallyballoon-4clr.jpg (GRAPHIC) — 54KB
• fc_clinicalresults-4clr.jpg (GRAPHIC) — 108KB
• lc_earlyfeasibility-4clr.jpg (GRAPHIC) — 39KB
• tb_milestones-4c.jpg (GRAPHIC) — 60KB
• tm245520d17_ex2-1img01.jpg (GRAPHIC) — 4KB
• tm245520d17_ex2-1img02.jpg (GRAPHIC) — 5KB
• tm245520d17_ex2-1img03.jpg (GRAPHIC) — 4KB
• tm245520d17_ex2-1img04.jpg (GRAPHIC) — 4KB
• tm245520d17_ex2-1img05.jpg (GRAPHIC) — 4KB
• tm245520d17_ex2-1img06.jpg (GRAPHIC) — 4KB
• tm245520d17_ex10-13img001.jpg (GRAPHIC) — 11KB
• tm245520d17_ex10-19cimg001.jpg (GRAPHIC) — 5KB
• tm245520d17_10-19dimg01.jpg (GRAPHIC) — 18KB
• tm245520d17_10-19eimg01.jpg (GRAPHIC) — 18KB
• tm245520d17_10-19fimg01.jpg (GRAPHIC) — 18KB
• tm245520d17_ex10-25img001.jpg (GRAPHIC) — 10KB
• 0001104659-24-122098.txt ( ) — 11861KB

RISK FACTORS

RISK FACTORS 12 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 48

USE OF PROCEEDS

USE OF PROCEEDS 50 DIVIDEND POLICY 51 CAPITALIZATION 52

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 95 MANAGEMENT 109 DIRECTOR COMPENSATION 115

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 118 CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS 128 PRINCIPAL STOCKHOLDERS 129

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 131 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 135 SHARES ELIGIBLE FOR FUTURE SALE 139

UNDERWRITING

UNDERWRITING 141 LEGAL MATTERS 149 EXPERTS 149 LIMITATION ON INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S LIABILITY 149 WHERE YOU CAN FIND MORE INFORMATION 149 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 We have not, and the underwriters have not, authorized anyone to provide you any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriters take responsibility for, or provide any assurance as to the reliability of, any other information others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the shares of our Common Stock. Our business, financial condition, results of operations and prospects may have changed since that date. For Investors Outside the United States (the "U.S.") : We have not, and the underwriters have not, done anything that would permit this offering or the possession or distribution of this prospectus or any free writing prospectus in connection with this offering in any jurisdiction where action for that purpose is required, other than in the U.S. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of Common Stock and the distribution of this prospectus and any such free writing prospectus outside the United States. See the section titled " Underwriting ." i TABLE OF CONTENTS BACKGROUND Anteris Technologies

View Full Filing

View this S-1 filing on SEC EDGAR